TY - JOUR AU - Giau Vo AU - Minh Nam Nguyen AU - Toi Vo PY - 2021/04/15 Y2 - 2024/03/28 TI - Role of fluid biomarkers in the early diagnosis of Alzheimer’s disease JF - Science and Technology Development Journal: Health Sciences JA - STDJHS VL - 2 IS - 1 SE - Narrative review DO - https://doi.org/10.32508/stdjhs.v2i1.458 UR - http://stdjhs.scienceandtechnology.com.vn/index.php/stdjhs/article/view/458 AB - Alzheimer’s disease (AD) is the most common form of dementia in the elderly, which is clinically characterized by the progressive deterioration of memory and other cognitive functions that results in the loss of autonomy and ultimately leading to death. Increasing life expectancy has resulted in AD becomes a global public health concern, especially in developing countries as Vietnam. While there is currently no effective treatment for the disease, early detection of AD is critical to slow disease progression, prevent long-term morbidity and mortality, as well as reducing healthcare spending. The diagnosis of AD currently relies on clinical criteria, including mental status assessment, neurological examination, and brain imaging tests. However, these imaging methods are conclusive only in the advanced stages of disease, whereas AD physiopathology begins several decades before onset of the first symptoms. It is therefore particularly important to identify potential biomarkers that can be used in the early detection of AD aim to evaluate the efficiency of therapeutic agents under testing and to thus accelerate the therapeutic discovery process. The aim of the review was to highlight the current knowledge as well as future perspectives on the role of biomarkers in screening, diagnosis, treatment and follow-up of Alzheimer’s disease. ER -